Cancer Biological Therapy Market Size, Share and Growth Outlook, 2026

Cancer Biological Therapy Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cancer Biological Therapy Market size is forecast to increase from $151.75 Billion in 2026 to $320.59 Billion in 2034 at a CAGR of 9.8% between 2026 and 2034.

The Cancer Biological Therapy market report provides detailed analysis and outlook of Cancer Biological Therapy segments including By Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Adoptive Cell Transfer, Antibody-Drug Conjugates, Cancer Vaccines, Cytokines and Interleukins, Oncolytic Virus Therapies, Targeted Gene Therapies), By Target Application (Solid Tumors, Hematologic Malignancies ), By Route of Administration (Intravenous, Subcutaneous Injection, Intratumoral, Oral Administration), By Phase of Development (Approved, Clinical Pipeline Therapies ), By End-User (Hospitals and Multi-Specialty Clinics, Specialized Cancer Treatment Centers, Academic Medical Centers and Research Institutions) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cancer Biological Therapy Industry Overview

Immunotherapy Combinations Expanding Cancer Biological Treatment Options

The cancer biological therapy industry continues to advance through the development of innovative immunotherapy combinations designed to improve outcomes across multiple cancer indications. A significant milestone involves Merck’s supplemental Biologics License Applications for KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX, a fixed-combination formulation incorporating berahyaluronidase alfa. Both therapies are being evaluated in combination with Padcev (enfortumab vedotin-ejfv) for perioperative treatment of cisplatin-eligible patients with muscle-invasive bladder cancer. The expansion of biological combination therapies highlights the industry's growing focus on integrating immune checkpoint inhibitors with complementary treatment modalities to enhance anti-tumor activity. These combination strategies are increasingly becoming central to oncology treatment protocols as researchers seek to improve disease control and long-term patient outcomes through synergistic biological mechanisms.

Personalized Neoantigen Therapies Driving Next-Generation Oncology Innovation

The cancer biological therapy industry is rapidly embracing personalized treatment approaches that utilize patient-specific biological information to generate highly targeted immune responses. Merck and Moderna have reported encouraging clinical progress with intismeran autogene (mRNA-4157/V940), an individualized neoantigen therapy built using messenger RNA technology. The platform is uniquely customized for each patient based on the specific DNA mutational profile of a surgically removed tumor. By encoding up to 34 patient-specific neoantigens, the therapy is designed to train the immune system to recognize and eliminate residual cancer cells while reducing the risk of recurrence. This personalized biological therapy model represents a significant advancement in precision oncology, combining genomic sequencing, mRNA engineering, and immunotherapy into a single treatment framework. The emergence of individualized neoantigen therapies is expanding the scope of biological cancer treatments beyond conventional monoclonal antibodies and checkpoint inhibitors.

Real-Time Digital Clinical Trials Enhancing Biological Therapy Development

Digital transformation is increasingly influencing the cancer biological therapy industry through the integration of real-time data collection and advanced clinical monitoring platforms. Aligning with new FDA-supported digital research frameworks, AstraZeneca initiated its Phase 2 TRAVERSE study focused on treatment-naïve mantle cell lymphoma patients. Conducted in collaboration with the University of Texas MD Anderson Cancer Center, the study utilizes continuous streaming metrics to evaluate biological therapeutic interventions and monitor safety and efficacy signals in real time. This approach enables researchers to capture dynamic cellular responses, accelerate data analysis, and improve decision-making throughout clinical development. The adoption of real-time monitoring technologies reflects a broader shift toward data-driven oncology research, where continuous biological insights support faster validation of emerging therapies and enhance the development of innovative cancer treatment platforms.

Cancer Biological Therapy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cancer Biological Therapy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Sanofi S.A., GSK plc, Eli Lilly and Company, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd.. The Cancer Biological Therapy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cancer Biological Therapy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cancer Biological Therapy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cancer Biological Therapy companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cancer Biological Therapy markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cancer Biological Therapy Market Competitive Benchmarking and Company Analysis

Leading companies in Cancer Biological Therapy industry include- F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Sanofi S.A., GSK plc, Eli Lilly and Company, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd.. The Cancer Biological Therapy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cancer Biological Therapy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cancer Biological Therapy market remains one of the strongest-performing segments in the country.
The US Cancer Biological Therapy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cancer Biological Therapy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cancer Biological Therapy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cancer Biological Therapy markets

Canada's strong Cancer Biological Therapy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cancer Biological Therapy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cancer Biological Therapy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cancer Biological Therapy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cancer Biological Therapy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cancer Biological Therapy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cancer Biological Therapy market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cancer Biological Therapy sales through 2034

France Cancer Biological Therapy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cancer Biological Therapy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cancer Biological Therapy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cancer Biological Therapy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cancer Biological Therapy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cancer Biological Therapy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cancer Biological Therapy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cancer Biological Therapy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cancer Biological Therapy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cancer Biological Therapy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cancer Biological Therapy Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cancer Biological Therapy Market Segmentation

By Therapy Type
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Adoptive Cell Transfer
Antibody-Drug Conjugates
Cancer Vaccines
Cytokines and Interleukins
Oncolytic Virus Therapies
Targeted Gene Therapies
By Target Application
Solid Tumors
Hematologic Malignancies
By Route of Administration
Intravenous
Subcutaneous Injection
Intratumoral
Oral Administration
By Phase of Development
Approved
Clinical Pipeline Therapies
By End-User
Hospitals and Multi-Specialty Clinics
Specialized Cancer Treatment Centers
Academic Medical Centers and Research Institutions

Top Companies in Cancer Biological Therapy Industry

F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
Merck & Co., Inc.
Sanofi S.A.
GSK plc
Eli Lilly and Company
Bayer AG
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025